Standard-of-care Systemic Therapy with or without SBRT in Patients with oligoprogressive Breast Cancer or NSCLC ("CURB Oligoprogression"): an open-label, randomised, controlled, Phase 2 Study

被引：0
|
作者：
Stritzke, Florian [1 ]
Held, Thomas [1 ]
机构：
[1] Univ klin Heidelberg, Heidelberg, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年 / 200卷 / 09期
关键词：
CELL LUNG-CANCER;
D O I：
10.1007/s00066-024-02261-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：850 / 852
页数：3
相关论文
共 50 条
  • [1] Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapyto Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
    Tsai, Chiaojung Jillian
    Yang, Jonathan
    Shaverdian, Narek
    Patel, Juber
    Shepherd, Annemarie F.
    Eng, Juliana
    Guttmann, David
    Yeh, Randy
    Gelblum, Daphna Y.
    Namakydoust, Azadeh
    Preeshagul, Isabel
    Modi, Shanu
    Seidman, Andrew
    Traina, Tiffany
    Drullinsky, Pamela
    Flynn, Jessica
    Zhang, Zhigang
    Rimner, Andreas
    Gillespie, Erin F.
    Gomez, Daniel R.
    Lee, Nancy Y.
    Berger, Michael
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Riaz, Nadeem
    Rudin, Charles M.
    Powell, Simon N.
    LANCET, 2024, 403 (10422): : 171 - 182
  • [2] Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
    Seery, Tara Elisabeth
    Nangia, Chaitali Singh
    Sender, Leonard S.
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
    Spigel, D.
    Garassino, M.
    Besse, B.
    Sacher, A.
    Barve, M.
    Cousin, S.
    Schenker, M.
    Rogan, D.
    Yadavilli, S.
    Acusta, A.
    Amit, O.
    Leighton-Swayze, A.
    Ballas, M.
    Hoos, A.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S404 - S405
  • [4] A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients
    Ingargiola, Rossana
    De Santis, Maria Carmen
    Iacovelli, Nicola Alessandro
    Facchinetti, Nadia
    Cavallo, Anna
    Ivaldi, Eliana
    Dispinzieri, Michela
    Franceschini, Marzia
    Giandini, Carlotta
    Romanello, Domenico Attilio
    Di Biaso, Simona
    Sabetti, Michela
    Locati, Laura
    Alfieri, Salvatore
    Bossi, Paolo
    Guglielmo, Mauro
    Macchi, Fabio
    Lozza, Laura
    Valdagni, Riccardo
    Fallai, Carlo
    Pignoli, Emanuele
    Orlandi, Ester
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [5] A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients
    Rossana Ingargiola
    Maria Carmen De Santis
    Nicola Alessandro Iacovelli
    Nadia Facchinetti
    Anna Cavallo
    Eliana Ivaldi
    Michela Dispinzieri
    Marzia Franceschini
    Carlotta Giandini
    Domenico Attilio Romanello
    Simona Di Biaso
    Michela Sabetti
    Laura Locati
    Salvatore Alfieri
    Paolo Bossi
    Mauro Guglielmo
    Fabio Macchi
    Laura Lozza
    Riccardo Valdagni
    Carlo Fallai
    Emanuele Pignoli
    Ester Orlandi
    Radiation Oncology, 15
  • [6] Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
    Tolaney, Sara M.
    Wardley, Andrew M.
    Zambelli, Stefania
    Hilton, John F.
    Troso-Sandoval, Tiffany A.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen R. D.
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Chapman, Sonya C.
    Price, Gregory L.
    Yang, Zhengyu
    Gainford, M. Corona
    Andre, Fabrice
    LANCET ONCOLOGY, 2020, 21 (06): : 763 - 775
  • [7] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [8] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [9] A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
    Oberstein, Paul Eliezer
    Eng, Cathy
    Van Cutsem, Eric
    Elez, Elena
    Ducreux, Michel
    Patel, Sejal
    Pang, Dona
    Milford, Leann
    Iwasawa, Ryota
    Schnepp, Robert W.
    Knoblauch, Roland
    Thayu, Meena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS279 - TPS279
  • [10] A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
    Trainer, Peter J.
    Newell-Price, John D. C.
    Ayuk, John
    Aylwin, Simon J. B.
    Rees, Aled
    Drake, William
    Chanson, Philippe
    Brue, Thierry
    Webb, Susan M.
    Fajardo, Carmen
    JavierAller
    McCormack, Ann, I
    Torpy, David J.
    Tachas, George
    Atley, Lynne
    Ryder, David
    Bidlingmaier, Martin
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (02) : 97 - 108
12345